The Consumer Medicine Information (CMI) is a leaflet written for people who have been prescribed this product. This information is intended for use in Australia only and does not replace advice from a healthcare professional. You should discuss the CMI with your healthcare professional if you have any questions or concerns.
For Healthcare Professionals – Product Information
The Product Information (PI) is intended to assist healthcare professionals in making decisions about treatment and provide advice on the appropriate use of this product. This information is intended for use in Australia only.
VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
This information is intended for healthcare professionals only. Please login/sign up to continue.
You are about to be redirected to the “IQVIA OneKey” healthcare professional authentication portal. By logging in (or signing up) for a OneKey account, you will be provided with access to the BioMarin Australia Healthcare Professional website.
You’re about to leave the BioMarin Australia website
The information that you are about to be referred to may not comply with the Australian regulatory requirements or be applicable to Australian users. For particulars specifically relevant to the Australian environment contact BioMarin Pharmaceutical Australia Pty Ltd or refer to the appropriate Product Information document.